TriangleNCT01535040 · OUTCOME
Retention
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 12 weeks
What was measured
Retention is defined as the percentage of participants who complete the 12 week visit
Analysis population: All randomized participants
Groups in this outcome
Arm I - Memantine
Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity. memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
Arm II - Placebo
Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity. placebo: Placebo by mouth through completion of 12 weeks.
| Group | Source count |
|---|---|
| Arm I - Memantine | 65 |
| Arm II - Placebo | 65 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I - Memantine | 53.8 | Not reported | 41.0 | 66.3 | Not reported |
| Arm II - Placebo | 67.7 | Not reported | 54.9 | 78.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 41.0
- upper Limit
- 66.3
- value
- 53.8
- group Id
- OG001
- lower Limit
- 54.9
- upper Limit
- 78.8
- value
- 67.7
- denoms
- counts
- group Id
- OG000
- value
- 65
- group Id
- OG001
- value
- 65
- units
- Participants
- description
- Retention is defined as the percentage of participants who complete the 12 week visit
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity. memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
- id
- OG000
- title
- Arm I - Memantine
- description
- Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity. placebo: Placebo by mouth through completion of 12 weeks.
- id
- OG001
- title
- Arm II - Placebo
- param Type
- NUMBER
- population Description
- All randomized participants
- reporting Status
- POSTED
- time Frame
- 12 weeks
- title
- Retention
- type
- PRIMARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice